Month: May 2023

VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) today announced the following executive and vice president appointments: Ian Anderson has been appointed SVP & Chief Commercial Officer, effective May 16, 2023. Mr. Anderson succeeds Réal Foley, who will retire in late November 2023. Mr. Foley will support transition activities across Teck’s Marketing and Logistics and strategic initiatives until his retirement. “Ian’s extensive experience and proven ability make him ideally suited to develop and implement an overall commercial strategy for Teck’s base metals and steelmaking coal businesses including key areas such as procurement, marketing, logistics and responsibility for our UK and Asia offices,” said CEO Jonathan Price. Mr. Anderson brings to...

CALGARY, Alberta, May 25, 2023 (GLOBE NEWSWIRE) — Eguana Technologies Inc. (“Eguana” or the “Company”) (TSX.V: EGT) (OTCQB: EGTYF) will post its financial results for its first quarter, ended March 31, 2023, on Tuesday May 30th. Eguana management will also host a conference call on Tuesday May 30th, 2023 at 5:30 p.m. eastern time (EDT) to discuss the results, provide a business update, and hold a question and answer period. Registration in advance is required. CONFERENCE CALL DETAILSDate: May 30, 2023Time: 5:30 PM EDT Telephone Access:Canada/USA Toll Free: 1-800-319-4610International Toll: +1-604-638-5340 To ensure the conference begins in a timely manner please dial in 10 minutes prior to the start time to register. Webcast: https://services.choruscall.ca/links/eguanatechnology2022q4.html About Eguana Technologies...

– SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose – AUSTIN, TX and DURHAM, NC, May 25, 2023 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of complete dose-escalation data from the Phase 1A monotherapy clinical trial of SL-172154 in PROC. These data will be featured in a poster presentation at the ASCO Annual Meeting, being held both virtually and in Chicago, IL from June 2-6, 2023. “We are excited to present data at ASCO that we...

New York, New York, May 25, 2023 (GLOBE NEWSWIRE) — Springwater Special Situations Corp. (Nasdaq: SWSS) (the “Company”) announced today that the Nasdaq Stock Market LLC (“Nasdaq”), by letter dated May 25, 2023 (the “Notice”), notified the Company that it was not in compliance with Nasdaq’s continued listing standards because the Company did not timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Quarterly Report”). As reported in the Form 12b-25 filed by the Company with the Securities and Exchange Commission on May 15, 2023, the Company is still in the process of compiling required information to complete the Quarterly Report. As a result, the Company required additional time to compile and verify the data required to be included in the Quarterly Report. Under Nasdaq rules, the Company now...

Columbus, OH, May 25, 2023 (GLOBE NEWSWIRE) — Mettler-Toledo International Inc. (NYSE:MTD) today announced the webcast of its presentation at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 8:30 a.m Eastern Time.  To hear a live webcast of the presentation, visit the investor relations page on the Company’s Web site at investors.mt.com.  A replay of the webcast will be available. METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences,...

Media Release COPENHAGEN, Denmark; May 25, 2023Oral presentations will highlight epcoritamab–bysp in combination with rituximab–lenalidomide (R2) in high-risk follicular lymphoma Poster presentations will highlight epcoritamab in lymphoma across multiple lines of therapy and histologies where high unmet needs existGenmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, IL and virtually, June 2-6, 2023, and at the 2023 European Hematology Association (EHA) Congress, being held in Frankfurt, Germany and virtually, June 8-11, 2023. Presentations will include data from clinical trials evaluating the efficacy of epcoritamab...